BioCryst Pharmaceuticals (BCRX) 10-K2022 FY Annual report

Filed: 27 Feb 23, 4:38pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ahead, alongside, America, American, Arabia, Astria, bad, benchmark, BioPharma, burden, CEE, cessation, climate, Colorado, compel, condensed, construed, copayment, Deferral, DOJ, domain, downturn, Eastern, exacerbated, Expert, FCA, fifteen, GmbH, Ia, Immunoglobulin, intangible, Interbank, IRA, IRC, KalVista, living, London, low, narrowly, obsolescence, overnight, Palestinian, pathology, pause, persuade, Pint, pipeline, preclude, Prekallikrien, presence, reauthorization, redirecting, relief, safer, Saudi, Sebetralstat, Society, SOFR, soil, space, subsection, sunset, Swixx, Tarpeyo, temporarily, twofold, upstream, USD, Utah, Virginia, virtual, worse

Removed: Abercrombie, accessing, Acid, activating, activin, Agonist, Alan, Alane, Babu, Callaghan, Certification, cohort, confirmation, countermeasure, deciding, delivering, domestic, dosing, duly, executing, exhibit, exploring, Fibrodysplasia, formatted, fused, Gamma, GCP, gene, George, Helen, hemorrhagic, herewith, HO, honest, Hutson, ideal, indemnification, indirectly, Ingram, Innovation, internally, Ipsen, ISDA, Jon, Jr, Junior, Kenneth, kinase, largest, Lee, lesser, Levin, Link, Master, Megan, met, Michael, Morgan, morphogenic, Mundipharma, mutation, Nancy, nation, novation, omitted, orally, Palovarotene, permanent, placebo, PoC, pose, prekallikrein, premature, President, progressiva, progressively, randomized, RAR, Relocation, resolve, respectfully, responsibly, Retinoic, Robert, Separation, servicing, Sheridan, shipment, signaling, signature, Sniecinski, soft, Stanley, stimulating, Stonehouse, structured, suspending, Thackray, thereunto, threat, tissue, tolerated, trauma, undersigned, Victoria, virulent, William, XBRL, Yarlagadda

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BCRX transcripts

BCRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

•Registration Statements (Form S-8 Nos. 333-231108, 333-239078, 333-245024, 333-259919 and 333-267193) pertaining to the BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan;

•Registration Statements (Form S-3 Nos. 333-145638, 333-153084, 333-217859, 333-237820 and 333-253719) of BioCryst Pharmaceuticals, Inc.;

•Registration Statements (Form S-8 Nos. 333-120345, 333-39484, 333-30751 and 333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated;

•Registration Statements (Form S-8 Nos. 333-90582, 333-239077 and 333-256624) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated;

•Registration Statement (Form S-8 No. 333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated, and the Employment Letter Agreement dated April 2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;

•Registration Statements (Form S-8 Nos. 333-176096, 333-211529, 333-218360, 333-228296, 333-231942, 333-239076, 333-256625 and 333-266132) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated;

•Registration Statements (Form S-8 Nos. 333-152570, 333-167830, 333-187193 and 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and the Employee Stock Purchase Plan, each as amended and restated

of our reports dated February 27, 2023, with respect to the consolidated financial statements of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2022.

/s/ Ernst & Young LLP

Raleigh, North Carolina

February 27, 2023